Skip to main content
. Author manuscript; available in PMC: 2014 May 21.
Published in final edited form as: Cancer Prev Res (Phila). 2010 Jan 26;3(2):148–159. doi: 10.1158/1940-6207.CAPR-09-0233

Figure 4.

Figure 4

Mean Ki-67 over time in all layers.

A. Baseline and 3-month time points show decreasing expression of Ki-67 with high-dose celecoxib over time in both current and former smokers who had both baseline and 3-month Ki-67 measurements. Total evaluable patients are 28 in former smokers group and 97 in current smoker group. Y-axis represents Ki-67 index.

B. Baseline and 3- and 6-month time periods show a similar trend for Ki-67 expression with high-dose celecoxib in both current and former smokers who had baseline, 3-month and 6-month Ki-67 measurements. Total evaluable patients are 10 in former smokers group and 37 in current smoker group. Placebo and low-dose celecoxib follow similar patterns, especially in current smokers. Y-axis represents Ki-67 index.